Module 4

Module 4: Evidence-Based CBD Clinical Applications

Peer-Reviewed Efficacy, PK & Regulatory Guidelines in Canines

Module 4: CBD Clinical Applications

Canine Osteoarthritis

Refractory Epilepsy

• Efficacy: Decreased CBPI pain scores

• Dosing: 2 mg/kg PO q12h with food

• Efficacy: ~33% seizure reduction

• Protocol: 2.5 mg/kg q12h add-on AED

PK & Hepatotoxicity

Regulatory Compliance

• Absorption: High lipid bioavailability

• Monitoring: Track ALT/ALP elevations

• Claims: Avoid unapproved label claims

• Quality: Verify batch COA profiles

← Previous Next →

Clinical Disclaimer

This course is for veterinary continuing education. It does not constitute veterinary advice or a recommendation to prescribe any specific product. No therapeutic claims are made for unapproved products.